Express Authority

In insurance, express authority refers to the authority given to an agent or broker in writing to perform specific acts or duties on behalf of the insurer. This type of authority is explicit and clearly stated, and it outlines the scope and limits of the agent's or broker's responsibilities.

Here are some key features of express authority:

• Written documentation: Express authority is given in writing, such as through a contract or agreement between the insurer and the agent or broker.

• Specific duties: The authority given is specific to certain duties or acts that the agent or broker is authorized to perform on behalf of the insurer.

• Limits and scope: The express authority outlines the limits and scope of the agent's or broker's responsibilities, making it clear what actions they are authorized to take and under what circumstances.

• Binding on insurer: Any actions taken by the agent or broker within the scope of their express authority are binding on the insurer.

Example: An insurer may grant an agent express authority to negotiate and sell insurance policies to customers within a certain geographic region. The agent would be authorized to conduct these activities, but their authority would not extend to making policy changes or settling claims on behalf of the insurer.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.